TICKERNERD
Menu
BDSXBDSXHealthcare · Diagnostics & Research

BDSX Stock Forecast: Biodesix, Inc. Price Predictions for 2026-2027

Last close, 14 Oct 2026
$24
−4.04% on the day

The 7 Wall Street analysts covering Biodesix, Inc. hold a median 12-month price target of $40 — +66.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 85 of 100 as at 14 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$263.8M
Ticker Nerd rank
85 / 100
Median analyst target
$40
Analysts covering
7
Revenue$26.9M+34.2% y/y
Operating income−$5.4M
Net income−$7.3M
Free cash flow−$1.8M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−9.2%
1M
−12.4%
YTD
+252.8%
1Y
+208.0%
From 52W high
−21.6%
From 52W low
+339.4%
$5
$31
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

BDSX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Biodesix, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 14 Oct 2026
85 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
97
Momentum
95
Growth
89
Size
64
Quality
63
Accruals
61
Issuance
38
Volatility
30
Value
18

Revisions (97): Analysts have, on balance, been raising their forecasts.

Value (18): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

BDSX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BDSX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40Jan 26Apr 26Jul 26Oct 26BDSXHigh $41Median $40Low $35

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says7 analysts
7 Buy0 Hold0 Sell
Low $35Median $40High $41

The green dot is the last close — the median target sits +66.7% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 5 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
13 Oct 2026TD CowenMaintainsBuy$30 → $40
25 Sept 2026HC Wainwright & Co.MaintainsBuy$27 → $38
10 Aug 2026Canaccord GenuityMaintainsBuy$27 → $35
10 Aug 2026Canaccord GenuityMaintainsBuy—
6 Aug 2026HC Wainwright & Co.MaintainsBuy$26 → $27
6 Aug 2026HC Wainwright & Co.MaintainsBuy—
25 June 2026Roth CapitalInitiatesBuy—
25 June 2026Roth CapitalInitiatesBuy$32
18 June 2026Canaccord GenuityMaintainsBuy—
18 June 2026Canaccord GenuityMaintainsBuy$22 → $27
15 June 2026HC Wainwright & Co.InitiatesBuy—
5 May 2026Canaccord GenuityMaintainsBuy—
27 Feb 2026William BlairUpgradeOutperform—
17 Feb 2026Canaccord GenuityMaintainsBuy—
19 Sept 2025Canaccord GenuityMaintainsBuy—
21 May 2025ScotiabankMaintainsSector Outperform—
14 May 2025Canaccord GenuityMaintainsBuy—
14 May 2025Craig-HallumMaintainsBuy—
14 May 2025Lake StreetMaintainsBuy—
14 May 2025William BlairDowngradeMarket Perform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BDSX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

BDSX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 14 Oct 2026, Biodesix, Inc. returned +208.0% against +17.5% for the S&P 500, dividends included.

BDSX vs S&P 500, last 12 monthsTotal return, rebased to 100
50100150200250300350400Jan 26Apr 26Jul 26Oct 26BDSXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

BDSX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
7
Analysts cutting
0
Fundamentals

Biodesix, Inc. (BDSX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−5.4×

Cheaper than 91% of US stocks

Price / sales
2.6×

Cheaper than 45% of US stocks

Price / book
28.8×

Cheaper than 3% of US stocks

EV / EBITDA
−20.4×

Cheaper than 90% of US stocks

Growth & margins
Revenue growth (YoY)
34.2%

Higher than 80% of US stocks

Earnings growth (YoY)
34.2%

Higher than 68% of US stocks

Gross margin
82.1%

Higher than 92% of US stocks

Operating margin
−20.0%

Higher than 21% of US stocks

Net margin
−27.0%

Higher than 14% of US stocks

Returns & dividend
Return on equity
−540.0%

Higher than 3% of US stocks

Return on assets
−14.1%

Higher than 23% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Biodesix, Inc. (BDSX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Biodesix, Inc. has a market value of $263.8M and an enterprise value of $305.6M.

  • Revenue in the twelve months to 30 June 2026: $102.9M. The latest quarter grew 34.2% year on year.

  • Net income over the same four quarters: −$27.8M, a −27.0% net margin.

  • Diluted earnings per share, trailing twelve months: $−3.17.

  • Free cash flow in the twelve months to 30 June 2026: −$20.4M.

  • Shares outstanding: 10.5M.

  • Trailing P/E: −5.4×; forward P/E: −113.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Biodesix, Inc. employs 334 people — $308K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 14 Oct 2026

Data provided by Twelve Data

Peers

BDSX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDiagnostics & Research
CompanyMarket capTKN rank
BDSXBiodesix, Inc.$263.8M
85
XGNExagen, Inc.$202.5M
65
MYGNMyriad Genetics, Inc.$388.1M
52
FLGTFulgent Genetics, Inc.$596.7M
51
IMDXInsight Molecular Diagnostics, Inc.$89.7M
36
QUCYQuantum Cyber NV$86.6M
6
CSTLCastle Biosciences, Inc.$966.4M
92

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Biodesix, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest BDSX news & analysis

Biodesix to Present New Real-World Evidence Supporting Integration of Nodify Lung® Testing into Routine Lung Nodule Care at CHEST 2026

GlobeNewsWire · 13 Oct 2026positive

Biodesix announced it will present new real-world evidence at CHEST 2026 regarding integration of Nodify Lung testing into routine lung nodule care. Sponsored and independent research will evaluate clinical utility, patient follow-up, and diagnostic test sequencing.

Why it matters — The presentations will provide BDSX watchers with research on how Nodify Lung testing may fit into routine care and patient follow-up.

Biodesix Expands MRD Testing With Tumor-Informed and Tumor-Naive Tests

Zacks Investment Research · 28 Sept 2026positive

Biodesix is advancing two blood-based minimal residual disease (MRD) testing programs, one tumor-informed and one tumor-naive, in collaboration with Bio-Rad and Thermo Fisher. The initiatives aim to broaden access to cancer monitoring.

Why it matters — Expanding its MRD testing portfolio through partnerships could broaden Biodesix's cancer-monitoring capabilities and reach in a growing diagnostic segment.

Biodesix Advances Two Complementary Approaches to Molecular Residual Disease (MRD) Monitoring

GlobeNewsWire · 24 Sept 2026positive

Biodesix is advancing two complementary approaches to molecular residual disease (MRD) monitoring, comprising tumor-informed and tumor-naïve programs that leverage the company's bioinformatics and diagnostics test development expertise.

Why it matters — BDSX watchers would care because this highlights the company's expansion into the MRD monitoring space, building on its existing diagnostics capabilities.

Biodesix Quality and Regulatory Executive, Brianna Phillips, to speak at upcoming RAPS and SOCRA Annual Meetings

GlobeNewsWire · 14 Sept 2026neutral

Biodesix announced that its Quality and Regulatory executive, Brianna Phillips, will speak at upcoming RAPS and SOCRA annual meetings. The company highlighted that its quality assurance and regulatory affairs expertise helps accelerate patient access to its laboratory testing, which supports improved outcomes for lung nodule patients.

Why it matters — This is notable for Biodesix watchers as it highlights the company's executive engagement and reinforces its focus on quality and regulatory processes that underpin access to its diagnostic testing.

Biodesix to Participate in Upcoming Investor Conferences

GlobeNewsWire · 3 Sept 2026neutral

Biodesix, Inc. announced that members of its leadership team will present at three upcoming investor conferences. The company shared this news via a press release from Louisville, Colorado.

Why it matters — The leadership team's presentations at investor conferences give BDSX watchers opportunities to hear directly from the company about its business.

FAQ

Frequently asked questions about BDSX stock

What is the BDSX stock price forecast for 2026-2027?

The 7 Wall Street analysts covering Biodesix, Inc. have a median 12-month price target of $40, with estimates ranging from $35 to $41. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is BDSX stock a buy right now?

Of the 7 analysts covering Biodesix, Inc., 7 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Biodesix, Inc. 85 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank BDSX?

As at 14 Oct 2026, Biodesix, Inc. ranks 85 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (97 of 100).

Will BDSX stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +66.7% from the last close, and Ticker Nerd's factor model ranks Biodesix, Inc. 85 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the BDSX stock forecast for 2030?

No analyst covering Biodesix, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BDSX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $35 to $41 over the next 12 months.

How has BDSX stock performed over the past year?

Biodesix, Inc. returned +208.0% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Biodesix, Inc. do?

Biodesix, Inc. is a diagnostic solutions company focused on blood-based testing and development services for lung disease, with a strong emphasis on lung cancer care.

What is the latest news on BDSX?

The most recent item we track (GlobeNewsWire, 13 Oct 2026): "Biodesix to Present New Real-World Evidence Supporting Integration of Nodify Lung® Testing into Routine Lung Nodule Care at CHEST 2026". Biodesix announced it will present new real-world evidence at CHEST 2026 regarding integration of Nodify Lung testing into routine lung nodule care. Sponsored and independent research will evaluate clinical utility, patient follow-up, and diagnostic test sequencing.

Company

About Biodesix, Inc.

Biodesix, Inc. is a diagnostic solutions company focused on blood-based testing and development services for lung disease, with a strong emphasis on lung cancer care. Biodesix provides commercial tests such as Nodify XL2 and Nodify CDT for lung nodule risk assessment, along with GeneStrat ddPCR, GeneStrat NGS, and VeriStrat to support diagnostic and treatment decisions in oncology. The company also serves biopharmaceutical, life sciences, and diagnostic partners with services that include biomarker discovery, assay design, clinical trial sample testing, regulatory support, reimbursement support, commercialization, and logistics. By combining laboratory diagnostics with research and development capabilities, Biodesix plays a specialized role in precision medicine and respiratory health, helping clinicians and industry customers address unmet needs in lung-related disease management.

CEO Mr. Scott Hutton · 334 employees · United States · https://www.biodesix.com